• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconValeant

Valeant

Page 11 of 12
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
HealthShort-seller: Is Valeant the pharmaceutical Enron?
By Laura LorenzettiOctober 21, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
HealthValeant eases up on strategy to buy up ‘mispriced drugs’
By Laura LorenzettiOctober 19, 2015
Hedge fund manager Bill Ackman
FinanceThe strange thing about Bill Ackman’s defense of Valeant’s drug prices
By Stephen GandelOctober 7, 2015
HealthThe drug price conundrum: a Q&A with Memorial Sloan Kettering’s Dr. Peter B. Bach
By Laura LorenzettiSeptember 29, 2015
MPWValeant had the hots for ‘female Viagra,’ Sprout CEO says
By Jen WiecznerAugust 20, 2015
Ackman, founder and CEO of hedge fund Pershing Square Capital Management, speaks at the Sohn Investment Conference in New York
FinanceBill Ackman: Valeant could be the next Berkshire Hathaway
By Jen WiecznerMay 4, 2015
SEC Chair Mary Jo White
FinanceSEC’s Mary Jo White criticizes shareholder activism and Bill Ackman deal
By Stephen GandelMarch 19, 2015
Actavis CEO Brenton Saunders and Allergan CEO David Pyotton pose together on the floor of the New York Stock Exchange
FinanceAllergan CEO: How to survive an activist attack
By Stephen GandelFebruary 12, 2015
Actavis CEO Brenton Saunders and Allergan CEO David Pyotton pose together on the floor of the New York Stock Exchange
FinanceAllergan CEO hands Botox maker to lawyer instead of consultant
By Stephen GandelNovember 17, 2014
Botox
FinanceActavis agrees to buy Botox-maker Allergan for $66 billion
By John KellNovember 17, 2014
FinanceDid Bill Ackman just kill the poison pill?
By Stephen GandelNovember 6, 2014
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
FinanceBill Ackman confirms Pershing Square Holdings IPO plan
By Tom Huddleston Jr.August 13, 2014
FinanceMorgan Stanley caught playing both sides of Allergan-Valeant fight
By Tom Huddleston Jr.June 16, 2014
Botox Treatment
FinanceAllergan and Valeant are both hypocrites
By Stephen GandelJune 2, 2014
FinanceValeant boosts bid to buy Botox-maker Allergan
By Laura LorenzettiMay 28, 2014
1...
  • 8
  • 9
  • 10
  • 11
  • 12
12
Most Popular
Law
DOGE cancelled a $349,000 grant to replace a museum’s HVAC after ChatGPT flagged it as DEI, court documents showAn image of a popular article
By Fortune EditorsMarch 19, 2026
Economy
Social Security has 6 years left. The fix that sounds cruelest may be the smartestAn image of a popular article
By Fortune EditorsMarch 19, 2026
Economy
Jerome Powell says you're right to blame data centers for making your bills more expensive: 'probably pushing inflation up'An image of a popular article
By Fortune EditorsMarch 19, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.